BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coppola N, Portunato F, Buonomo AR, Staiano L, Scotto R, Pinchera B, De Pascalis S, Amoruso DC, Martini S, Pisaturo M, Coppola C, Gentile I. Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. J Nephrol 2019;32:763-73. [PMID: 30977055 DOI: 10.1007/s40620-019-00608-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Freekh DA, Helmy MW, Said M, El-Khodary NM. The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection. Saudi Pharm J 2021;29:1120-8. [PMID: 34703365 DOI: 10.1016/j.jsps.2021.08.006] [Reference Citation Analysis]
2 Minutolo R, Ravera M, Cupisti A, Nappi F, Mandreoli M, Soragna G, Ferraro PM, De Nicola L; Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology. Prevalence of hepatitis-C virus infection in non-dialysis CKD patients: a multicenter study in renal clinics. Nephrol Dial Transplant 2021:gfab190. [PMID: 34051092 DOI: 10.1093/ndt/gfab190] [Reference Citation Analysis]
3 Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4:713-721. [PMID: 32782961 DOI: 10.1002/jgh3.12324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. J Gastroenterol Hepatol 2021. [PMID: 34618379 DOI: 10.1111/jgh.15703] [Reference Citation Analysis]
5 Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, Tonizzo M, Gitto S, Andreone P, Gattei V. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses 2021;13:2249. [PMID: 34835054 DOI: 10.3390/v13112249] [Reference Citation Analysis]
6 Nevola R, Rinaldi L, Zeni L, Romano C, Marrone A, Galiero R, Pafundi PC, Acierno C, Vetrano E, Adinolfi LE. Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2021;15:643-56. [PMID: 33445990 DOI: 10.1080/17474124.2021.1877136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Persico M, Aglitti A, Caruso R, Calvanese G, Di Siervi P, Masarone M; the MISTRAL Study Group. Real‐life efficacy and safety of glecaprevir/pibrentasvir in HCV‐infected patients with chronic kidney disease. GastroHep 2019. [DOI: 10.1002/ygh2.351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Scotto R, Buonomo AR, De Pascalis S, Nerilli M, Pinchera B, Staiano L, Mercinelli S, Cattaneo L, Stanzione M, Stornaiuolo G, Martini S, Messina V, Coppola C, Coppola N, Gentile I. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results. Expert Rev Gastroenterol Hepatol 2021;15:1057-63. [PMID: 33573411 DOI: 10.1080/17474124.2021.1890029] [Reference Citation Analysis]
10 Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore) 2020;99:e18948. [PMID: 32028404 DOI: 10.1097/MD.0000000000018948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]